OREANDA-NEWS. October 08, 2015. Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, today announces that six scientific presentations on the Company's ImmunoBody® and Moditope® immunotherapy platforms will be delivered at the 15th International Conference on Progress in Vaccination against Cancer (PIVAC-15). The presentations exemplify the growing body of data that are emerging from these platform technologies that suggest that they could be potentially important approaches to delivering effective and complementary immunotherapies to treat a range of cancers.

The six presentations are as follows:

·      "Citrullinated vimentin, which is presented on MHC-II on tumour cells, is a novel rejection target for CD4 T cells" (Moditope®)

·      "A clinical trial of a DNA vaccine (SCIB1) that targets dendritic cells in vivo in fully resected melanoma patients; a vaccine to prevent disease recurrence?" (SCIB1 ImmunoBody®)

·      "SCIB1 DNA vaccination synergises with PD-1 blockade to induce efficient tumour therapy of poorly immunogenic tumours" (SCIB1 ImmunoBody®)

·      "SCIB2 targets NY-ESO-1 epitopes to induce potent anti-tumour immunity which is enhanced by Treg depletion or checkpoint blockade" (SCIB2 ImmunoBody®)

·      "Adjuvant choice modulates self antigen specific CD4 responses generated by peptide vaccination" (Moditope®)

·      "Anti-tumour immune responses to citrullinated enolase" (Moditope®)

Prof Lindy Durrant, Joint CEO of Scancell and Professor of Cancer Immunotherapy at Nottingham University, commented: "Scancell's presentations at this important conference exemplify the growing body of exciting data emerging from both our SCIB1 clinical trial and our ImmunoBody®, and Moditope®, immunotherapy technology platforms, and provide a solid foundation for building a broad immuno-oncology franchise in the future."